Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 46.61% | $4.85B | 0.35% |
IBB | 45.51% | $5.17B | 0.45% |
GNOM | 44.34% | $39.83M | 0.5% |
BBH | 39.69% | $326.56M | 0.35% |
PBE | 38.79% | $215.67M | 0.58% |
IWC | 37.23% | $772.99M | 0.6% |
FBT | 37.20% | $1.00B | 0.56% |
ARKG | 36.96% | $914.43M | 0.75% |
IWO | 35.13% | $11.31B | 0.24% |
XPH | 35.07% | $137.67M | 0.35% |
IWM | 35.04% | $63.66B | 0.19% |
VTWO | 34.89% | $12.07B | 0.07% |
PTH | 34.62% | $98.02M | 0.6% |
KJAN | 34.22% | $304.58M | 0.79% |
SCHA | 33.98% | $16.85B | 0.04% |
NUSC | 33.98% | $1.14B | 0.31% |
IWN | 33.80% | $11.00B | 0.24% |
CPRJ | 33.72% | $48.36M | 0.69% |
BBRE | 33.52% | $896.49M | 0.11% |
VIG | 33.48% | $89.59B | 0.05% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTCT | -26.82% | $26.25M | +79.76% | 0.00% |
ACRS | -11.61% | $140.77M | +9.24% | 0.00% |
MNOV | -11.34% | $68.66M | +2.19% | 0.00% |
GFI | -10.75% | $19.05B | +26.67% | 2.57% |
CBOE | -9.07% | $23.50B | +22.83% | 1.09% |
DRD | -8.87% | $1.25B | +54.36% | 1.87% |
VHC | -7.54% | $35.49M | +75.53% | 0.00% |
HMY | -6.68% | $9.18B | +45.90% | 1.15% |
FMTO | -6.27% | $46.19M | -99.95% | 0.00% |
BCE | -6.11% | $19.88B | -36.69% | 13.03% |
IAG | -5.49% | $3.68B | +41.28% | 0.00% |
K | -4.45% | $28.59B | +32.73% | 2.75% |
SE | -4.28% | $88.93B | +122.54% | 0.00% |
FLNG | -3.48% | $1.35B | -15.35% | 12.13% |
EGO | -3.39% | $3.80B | +12.20% | 0.00% |
CORT | -3.12% | $7.93B | +159.07% | 0.00% |
AGI | -3.05% | $10.55B | +45.73% | 0.39% |
EDSA | -2.98% | $14.12M | -57.59% | 0.00% |
NEUE | -2.96% | $61.07M | +15.93% | 0.00% |
CREG | -2.90% | $18.45M | -33.10% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTL | 0.02% | $368.52M | 0.07% |
XBIL | -0.03% | $778.12M | 0.15% |
SCHP | -0.04% | $12.75B | 0.03% |
BWX | 0.05% | $1.42B | 0.35% |
PTBD | -0.07% | $158.43M | 0.6% |
FLGV | 0.12% | $978.56M | 0.09% |
CARY | -0.24% | $347.36M | 0.8% |
GLTR | 0.44% | $1.32B | 0.6% |
TYA | -0.46% | $150.60M | 0.15% |
AGZ | 0.48% | $608.43M | 0.2% |
CORN | 0.50% | $49.32M | 0.2% |
IEF | 0.57% | $34.36B | 0.15% |
RING | 0.57% | $1.37B | 0.39% |
SHYD | -0.58% | $318.28M | 0.35% |
BILZ | 0.71% | $901.37M | 0.14% |
STXT | 0.72% | $134.38M | 0.49% |
NEAR | 0.73% | $3.27B | 0.25% |
SPTI | -0.74% | $8.76B | 0.03% |
IBTO | 0.75% | $338.77M | 0.07% |
SMB | 0.75% | $269.27M | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ZNTL | 46.81% | $89.94M | -89.40% | 0.00% |
IRON | 46.10% | $1.72B | +53.49% | 0.00% |
IMNM | 44.57% | $696.97M | -41.96% | 0.00% |
OCUL | 43.02% | $1.20B | +19.40% | 0.00% |
ZYME | 42.85% | $830.40M | +31.63% | 0.00% |
SNDX | 41.20% | $800.24M | -54.07% | 0.00% |
IDYA | 40.93% | $1.58B | -55.16% | 0.00% |
RCUS | 40.56% | $922.26M | -48.09% | 0.00% |
APGE | 39.78% | $2.38B | -23.86% | 0.00% |
RCKT | 38.91% | $694.91M | -71.75% | 0.00% |
STOK | 38.59% | $536.69M | -38.94% | 0.00% |
KALV | 38.47% | $600.07M | +1.60% | 0.00% |
DNTH | 38.39% | $619.72M | -24.31% | 0.00% |
KYMR | 38.13% | $1.97B | -16.13% | 0.00% |
RVMD | 38.10% | $7.44B | -0.25% | 0.00% |
AUTL | 38.02% | $393.89M | -63.18% | 0.00% |
BEAM | 37.70% | $1.78B | -28.93% | 0.00% |
VRDN | 37.28% | $1.05B | -5.25% | 0.00% |
ATXS | 37.10% | $240.41M | -55.58% | 0.00% |
CGEM | 37.07% | $455.00M | -67.85% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.34% | $116.60M | 0.85% |
TAIL | -26.92% | $140.64M | 0.59% |
BTAL | -19.21% | $361.71M | 1.43% |
IVOL | -17.99% | $353.50M | 1.02% |
TPMN | -14.06% | $31.59M | 0.65% |
CTA | -12.88% | $1.06B | 0.76% |
XHLF | -12.70% | $1.46B | 0.03% |
STPZ | -8.59% | $452.72M | 0.2% |
CLIP | -8.45% | $1.51B | 0.07% |
VTIP | -8.37% | $14.75B | 0.03% |
ULST | -8.01% | $632.05M | 0.2% |
GSST | -7.50% | $873.92M | 0.16% |
STIP | -7.50% | $11.89B | 0.03% |
TDTT | -7.41% | $2.51B | 0.18% |
PALL | -7.36% | $338.98M | 0.6% |
XONE | -7.10% | $608.48M | 0.03% |
UTWO | -6.12% | $384.77M | 0.15% |
JMST | -6.05% | $3.68B | 0.18% |
CANE | -6.01% | $10.45M | 0.29% |
SPTS | -5.82% | $5.74B | 0.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LRN | -0.05% | $6.83B | +124.05% | 0.00% |
CHD | 0.07% | $23.64B | -9.90% | 1.20% |
DXCM | 0.10% | $34.10B | -33.46% | 0.00% |
UNH | -0.15% | $286.56B | -38.93% | 2.66% |
LTM | -0.16% | $10.85B | -96.77% | 2.73% |
T | 0.20% | $201.62B | +59.93% | 3.95% |
CCEC | -0.26% | $1.02B | +3.91% | 2.57% |
BVN | 0.32% | $3.71B | -18.83% | 0.00% |
CATO | -0.33% | $53.69M | -49.06% | 12.52% |
NCMI | -0.37% | $477.18M | +3.06% | 0.58% |
TBRG | 0.38% | $375.89M | +178.00% | 0.00% |
STG | 0.38% | $28.09M | -38.64% | 0.00% |
TGI | -0.40% | $1.99B | +70.70% | 0.00% |
B | 0.42% | $31.29B | +1.56% | 2.16% |
EQNR | 0.48% | $63.19B | -14.90% | 5.99% |
BBDO | -0.50% | $13.09B | +11.40% | 1.47% |
COR | -0.50% | $56.72B | +32.41% | 0.73% |
TPB | -0.52% | $1.31B | +120.36% | 0.39% |
KNOP | -0.55% | $229.11M | +22.34% | 1.56% |
DOGZ | 0.55% | $276.89M | +164.60% | 0.00% |
Finnhub
Hemophagocytic Lymphohistiocytosis / Hyperinflammatory Syndrome Following High Dose AAV9 Therapy Aimee Donald, MBChB, PhD 2025 ASGCT Meeting 16 May...
Finnhub
Neurogene Inc. announced an oral presentation at the American Society of Gene and Cell Therapy Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe...
Yahoo
NEW YORK, May 16, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic expos
Yahoo
NEW YORK, May 09, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates.
Finnhub
NEW YORK — NEW YORK — Neurogene Inc. on Friday reported a loss of $22.6 million in its first quarter. On a per-share basis, the New York-based company said it had a loss of $1.08. The...
Yahoo
NEW YORK, May 08, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 1,755 shares of the Company’s common stock to one new employee (the "Inducement Grants") on May 3, 2025 (the "Grant Date"). The Inducement Grant
Current Value
$20.391 Year Return
Current Value
$20.391 Year Return